Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Business Wire
Webcast and Conference Call Today at 4:30 p.m. ETOn track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in early 2021 Readouts from two clinical trials in hepatitis B virus program expected in the second quarter of 2021Initiated Phase 1 study of EDP-297, a highly potent and targeted follow-on farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis; initial clinical data expected in the second quarter of 2021 Royalty revenue for the quarter was $23.6 millionCash and marketable securities totaled approximately $419 million at September 30, 2020 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 3
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire
- Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
ENTA
Earnings
- 5/6/24 - Miss
ENTA
Analyst Actions
- 2/8/24 - JP Morgan
ENTA
Sec Filings
- 5/6/24 - Form 8-K
- 5/1/24 - Form 4
- 5/1/24 - Form 3
- ENTA's page on the SEC website